Prevalence of and Factors Associated with Sarcopenic Obesity in People Living with HIV
Article Sidebar
Main Article Content
Abstract
Objective:
To determine the prevalence and identify factors associated with sarcopenic obesity (SO) among people living with HIV (PLWH).
Material and Methods:
A cross-sectional study was conducted between September 2024 and May 2025 among 312 PLWH aged 20–79 years attending Siriraj Hospital. All participants had been diagnosed with HIV for at least 12 months. Sarcopenia was assessed using handgrip strength and the five-time chair stand test, while body composition was evaluated by bioelectrical impedance analysis.
Results:
The prevalence of SO was 7.3% (95% CI: 4.87–10.81%). While no significant associations were found in initial multivariable analyses, dose–response analysis revealed relationships between cumulative exposure to specific antiretroviral therapy (ART) and SO. A significant trend was observed with protease inhibitors (PIs). Stavudine (d4T) exposure was significantly associated with SO in the highest quartile, suggesting a threshold effect. Abacavir (ABC) also showed a strong association, particularly at the third quartile, with a significant dose–response trend.
Conclusions:
The findings suggest that certain ART regimens, especially prolonged exposure to PIs, stavudine, and abacavir, may contribute to the development of SO in PLWH. These insights underscore the importance of individualized ART management and the need for further longitudinal studies to understand the long-term metabolic impact of ART.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
Donini LM, Busetto L, Bischoff SC, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts. 2022;15(3):321-35. doi:10.1159/000521241.
Gao Q, Mei F, Shang Y, et al. Global prevalence of sarcopenic obesity in older adults: a systematic review and meta-analysis. Clin Nutr. 2021;40(7):4633-41. doi:10.1016/j.clnu.2021.06.009.
Wei S, Nguyen TT, Zhang Y, et al. Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management. Front Endocrinol. 2023;14:1185221. doi:10.3389/fendo.2023.1185221.
Ciudin A, Simó-Servatd A, Palmasa F, et al. Obesidad sarcopénica: un nuevo reto en la clínica práctica. Endocrinol Diabetes Nutr. 2020;67:672–81. doi:10.1016/j.endinu.2020.03.004.
Roh E, Choi KM. Health consequences of sarcopenic obesity: a narrative review. Front Endocrinol. 2020;11:332. doi:10.3389/fendo.2020.00332.
Ji T, Li Y, Ma L. Sarcopenic obesity: an emerging public health problem. Aging Dis. 2022;13(2):379-388. doi:10.14336/AD.2021.1006.
Abiri B, Hosseinpanah F, Seifi Z, et al. The implication of nutrition on the prevention and improvement of age-related sarcopenic obesity: a systematic review. J Nutr Health Aging. 2023;27(10):842-52. doi:10.1007/s12603-023-1986-x.
Oliveira VHF, Borsari AL, Webel AR, et al. Sarcopenia in people living with HIV: a systematic review and meta-analysis. Eur J Clin Nutr. 2020;74:1009–21. doi:10.1038/s41430-020-0637-0.
Konishi K, Nakagawa H, Asaoka T, et al. Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition. Medicine (Baltimore). 2022;101(42):e31349. doi:10.1097/MD.0000000000031349.
Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379-89. doi:10.1093/cid/ciz999.
Gallagher D, Heymsfield SB, Heo M, et al. Healthy percentage body fat ranges. Am J Clin Nutr. 2000;72:694-701. doi:10.1093/ajcn/72.3.694.
Craig CL, Marshall AL, Sjostrom M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381–95. doi:10.1249/01.MSS.0000078924.61453.FB.
Murawiak M, Krzymińska-Siemaszko R, Kaluźniak-Szymanowska A, et al. Sarcopenia, obesity, sarcopenic obesity and risk of poor nutritional status in Polish older people. Nutrients. 2022;14:2889. doi:10.3390/nu14142889.
Osuna-Padilla IA, Vargas A, Rosa A, et al. Sarcopenic obesity is associated with lower frequency of CD4+ T cells and high prevalence of metabolic syndrome in people living with HIV. Clin Nutr. 2018;37(S1):S21. doi:10.1016/j.clnu.2018.06.1138.
World Health Organization. Prevalence of obesity among adults (BMI ≥30). Global Health Observatory (GHO) data; 2022.
Chen TP, Kao HH, Ogawa W, et al. The Asia-Oceania consensus: definitions and diagnostic criteria for sarcopenic obesity. Obes Res Clin Pract. 2025;19(3):185-192. doi:10.1016/j.orcp.2025.05.001.
Dos-Santos-Quaresma MVL, Lima-Ribeiro SM. Sarcopenia in persons living with HIV under antiretroviral therapy: literature review. AIDS Rev. 2022;24(1):1–15. doi:10.24875/AIDSRev.21000018.
Milic J, Calza S, Cantergiani S, et al. Sarcopenic obesity phenotypes in patients with HIV: implications for cardiovascular prevention and rehabilitation. Can J Cardiol. 2023;39(11S):S359-S367. doi:10.1016/j.cjca.2023.08.027.
Smith ED, Malvestutto C, Ribaudo HJ, et al. Cardiovascular hazards of abacavir- versus tenofovir-containing antiretroviral therapies: insights from an analysis of the REPRIEVE trial cohort. Open Forum Infect Dis.2025;12(4):ofaf177. doi:10.1093/ofid/ofaf17.
